Aspirin vs Ibuprofen for Gastric Ulcer Risk

Comparative Gastric Ulcer Risk

The American College of Gastroenterology recommends low-dose aspirin (75-100 mg daily) with proton pump inhibitor (PPI) co-therapy for patients requiring anti-inflammatory or antiplatelet therapy who are at risk for gastric ulcers, as aspirin provides cardiovascular protection while PPI co-therapy reduces ulcer risk to near-baseline levels 1, 2
Low-dose aspirin (75 mg daily) doubles the risk of upper GI bleeding compared to non-users, with risk increasing dose-dependently, according to the American Heart Association 1
Aspirin 75 mg carries an odds ratio of 2.3 for peptic ulcer bleeding, 150 mg has OR 3.2, and 300 mg has OR 3.9, as reported by the American College of Chest Physicians 2
No dose of aspirin is completely free of bleeding risk, but 75-81 mg daily is the recommended dose for cardiovascular protection with lowest GI toxicity, according to the American College of Cardiology 1
Ibuprofen at low analgesic doses is less ulcerogenic than other NSAIDs, but at full anti-inflammatory doses (≥2400 mg/day), gastric bleeding risk becomes comparable to other NSAIDs, as stated by the American Gastroenterological Association 1, 4

For patients requiring both aspirin and NSAID therapy, the American College of Gastroenterology recommends using COX-2 inhibitor plus PPI or misoprostol 1, 5
The combination of low-dose aspirin (80-100 mg) plus esomeprazole 20 mg twice daily is superior to clopidogrel alone for preventing recurrent ulcer bleeding, with a recurrence rate of 0.7% vs 8.6%, as reported by the American College of Chest Physicians 2, 3
The American Heart Association recommends avoiding all NSAIDs if possible in very high-risk patients, and using COX-2 inhibitor plus PPI and/or misoprostol if absolutely necessary 1

PPIs are superior to H2-receptor antagonists for both healing and preventing NSAID-associated ulcers, according to the American Gastroenterological Association 6
Omeprazole heals and prevents ulcers more effectively than ranitidine in patients requiring continuous NSAID therapy, as reported by the American College of Chest Physicians 2, 3
H2-antagonists reduce duodenal ulcer risk but are inadequate for gastric ulcer prevention, making them less effective overall than PPIs, as stated by the American College of Gastroenterology 6
Testing for H. pylori should be performed in all patients with ulcers, as eradication prevents recurrent bleeding and ulcer recurrence, according to the American Gastroenterological Association 6
Triple therapy (PPI + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 14 days) is first-line treatment for H. pylori infection, as recommended by the American College of Gastroenterology 6

Switching from aspirin to other antiplatelet agents like clopidogrel does not reduce GI bleeding risk and may increase it, as reported by the American College of Cardiology 5
Poor compliance with gastroprotective agents increases NSAID-induced upper GI adverse events 4-6 fold, according to the American Gastroenterological Association 6